Tuesday, June 5, 2018

Genomic Health (GHDX) Soared To A New High On Study Results

Results from the TAILORx study, which were presented at the American Society of Clinical Oncology meeting in Chicago and published in the New England Journal of Medicine, show that 70% of women with early-stage breast cancer can skip chemotherapy following the removal of their tumors. The results were from a study of the Oncotype DX test from Genomic Health (GHDX).

from RTT - Before the Bell https://ift.tt/2kQdsXW
via IFTTT

No comments:

Post a Comment